Premium
Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR‐2 inhibitors
Author(s) -
Ravula Parameshwar,
Vamaraju Harinadha Babu,
Paturi Manichandrika,
Sharath Chandra Janivara Nanjunde Gowda Narendra
Publication year - 2018
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201700234
Subject(s) - in silico , docking (animal) , pyrazole , chemistry , in vitro , ic50 , mtt assay , stereochemistry , structure–activity relationship , cell culture , mcf 7 , cancer cell , combinatorial chemistry , pharmacology , biochemistry , cancer , human breast , biology , medicine , gene , genetics , nursing
As the blockade of the VEGFR‐2 signaling pathway is a viable approach in cancer therapy, the present study focuses on a series of pyrazole based VEGFR‐2 inhibitors that were designed on the basis of the hybridization approach, supported by docking and in silico computational studies. The designed compounds were synthesized through facile synthetic methods and the structures were confirmed by 1 H NMR, 13 C NMR, MS and elemental analysis. The compounds were screened for in vitro antiproliferative activity against the HT‐29 (human colon cancer) and MCF‐7 (human breast cancer) cell lines by MTT assay. The compounds were also studied for in vitro inhibitory activity against VEGFR‐2 kinase. Among all the tested compounds, compound 6h emerged as a potent agent in the antiproliferative study against HT‐29 and MCF‐7 cells, with IC 50 values of 2.36 and 6.59 μM, respectively. Moreover, the same compound exhibited the highest VEGFR‐2 inhibitory activity with an IC 50 value of 1.89 μM. In docking studies, the designed compounds showed similar and essential key interactions as those of known VEGFR‐2 inhibitors. The present study may lead to new molecules in the development of anticancer agents targeting VEGFR‐2.